Pharming Group (Euronext: PHARM / Nasdaq: PHAR) announced the filing of its 2025 Annual Report and the 2025 Annual Report on Form 20-F with the U.S. SEC on April 2, 2026. The Annual Report for the year ended December 31, 2025 is available online at the company's annual report site and Investors pages.
The Form 20-F will be accessible via the company's Investors/SEC filings page and through the SEC website once posted.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
This announcement highlighted Pharming’s completion of its regular reporting cycle by filing the 202...
Analysis
This announcement highlighted Pharming’s completion of its regular reporting cycle by filing the 2025 Annual Report and related Form 20-F for the year ended December 31, 2025. The filing provided investors with comprehensive financial statements, risk factors, and management discussion. With no specific figures or new strategic initiatives summarized in the release, investors would typically focus on the detailed contents of the report itself to assess performance, balance sheet strength, and any updated disclosures or risks.
Report year2025Annual Report year ended December 31, 2025
Year-end dateDecember 31, 2025Fiscal year end referenced in Annual Report
Announcement dateApril 2, 2026Date of Annual Report and Form 20-F filing announcement
Key Terms
form 20-f, u.s. securities and exchange commission, sec filings
3 terms
form 20-fregulatory
"The Company also announced the filing of its Annual Report on Form 20-F with the U.S."
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
u.s. securities and exchange commissionregulatory
"Form 20-F with the U.S. Securities and Exchange Commission (SEC)."
The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.
sec filingsregulatory
"The 2025 Annual Report on Form 20-F can be found under Investors/SEC filings on Pharming.com"
SEC filings are formal documents companies must send to the U.S. Securities and Exchange Commission that disclose key financial results, operations, risks and insider transactions. Think of them as a company’s official report card and instruction manual combined: they provide investors reliable, standardized facts used to evaluate value, spot risks, and compare companies, so missing or misleading filings can materially affect investment decisions.
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available at annualreport.pharming.com and under Investors/Financial documents on the Pharming.com website.
The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report on Form 20-F can be found under Investors/SEC filings on Pharming.com and through the SEC website once it has been filed.
About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.
Where can investors find Pharming Group's 2025 Annual Report (PHARM)?
The 2025 Annual Report is available online at annualreport.pharming.com. According to Pharming, investors can also access it under Investors/Financial documents on the company's website for download and review.
Has Pharming Group filed its 2025 Annual Report on Form 20-F (PHARM) with the SEC?
Yes, Pharming has filed the 2025 Annual Report on Form 20-F with the SEC. According to Pharming, the Form 20-F is available under Investors/SEC filings on the company website and on the SEC site when posted.
What period does Pharming Group's 2025 Annual Report cover for PHARM?
The 2025 Annual Report covers the year ended December 31, 2025. According to Pharming, the report contains the company's annual disclosures for that fiscal year and is available on the investor pages.
When was Pharming Group's 2025 Annual Report and Form 20-F announced (PHARM)?
Pharming announced the filings on April 2, 2026. According to Pharming, both the Annual Report and the Form 20-F filings were confirmed publicly on that date for investor access.
How can U.S. investors access Pharming Group's Form 20-F for 2025 (PHARM)?
U.S. investors can access the 2025 Form 20-F via the SEC website once posted and on the company's Investors/SEC filings page. According to Pharming, the document will be available through both channels for review.
